Analytical Data
-
Gene name
PDE7A1
- Application
-
Alternative Names
High affinity 3',5'-cyclic-AMP phosphodiesterase 7A; HCP1; TM22; cAMP-specific phosphodiesterase 7A; PDE7A; Homo sapiens; Human; Hydrolase; 3.1.4.53
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13946-2
-
Expression Region
S130-S482
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PDE7A1, or phosphodiesterase 7A1, is an important enzyme that plays a crucial role in the regulation of intracellular levels of cyclic nucleotides, specifically cyclic AMP (cAMP), which is pivotal in various cellular signaling pathways. Research into PDE7A1 has gained attention due to its implications in several physiological and pathological processes, including inflammation, neuronal signaling, and metabolic regulation. Dysregulation of cAMP levels has been associated with various diseases, including asthma, depression, and certain cancers. Consequently, PDE7A1 is considered a potential therapeutic target for drug development aimed at modulating cAMP signaling. The focus on recombinant protein studies of PDE7A1 allows for a deeper understanding of its structure, function, and the mechanisms governing its activity. By producing and characterizing recombinant PDE7A1, researchers can investigate the enzyme's kinetic properties, inhibitor binding, and interactions with other cellular components. This knowledge could lead to the development of selective inhibitors or modulators with therapeutic potential. Overall, the study of recombinant PDE7A1 is essential for translating basic research into clinical applications, providing insights into the enzyme's role in health and disease.
